Arima Genomics Completes Series A Financing

Genomics of Arima, Inc. , a company focused on research tools to accelerate understanding of the genome sequence and structure towards their role in human health and disease, announces the completion of its Series A funding round Agilent Technology, Inc. (NYSE: a) and Cowin Venture led this round, together with Vectr Ventures and the Berkeley Catalyst Fund.

“Agilent is investing in industry partners to advance the development of new technologies that will accelerate the pace of scientific discovery,” said Tad Weems, Managing Director of Agilent’s Early Stage Partnership Programme. “Arima has the potential to unlock new genomic applications by leading the community’s transition from focusing on sequence alone to sequence and structure. “That’s right.

The proceeds from this funding will be directed towards the expansion of Arima’s commercial efforts, the development of new applications to the existing Arima HiC platform, including the addition of structural analysis capabilities to conventional chromatin immunoprecipitation via HiChIP, and the development of new products, including smooth-covered HiC applications for gap-less de novo assemblies and population sequences. The funding will also support the expansion of Arima’s operations and enhance customer service and support experience.

“Since the initial product launch in 2018, Arima has shown remarkable success in building customer confidence as demonstrated by rapid customer and revenue growth,” said Siddarth Selvaraj, CEO and co-founder of Arima Genomics, Inc. “We’re excited to invite our investors to Arima’s fascinating journey and we’re thrilled to partner with them to drive the next phase of growth. “That’s right.

About the Genomics of Arima

Genomics of Arima, Inc. A biotechnology company that aims to accelerate the understanding of the genome sequence and structure Please visit www to learn more. Arimenomics Come on,

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Arima%20Genomics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co